CureLab Oncology is a biotechnology company developing new anti-cancer biologics. CureLab Oncology is committed to creating a family of revolutionary therapies for oncology patients in order to help prolong their lives.
CureLab Oncology's lead product, Elenagen™, is a plasmid (supercoiled circular DNA) encoding gene p62/SQSTM1. Elenagen™ reverses tumor grade, changes tumor microenvironment, enhances the anti-cancer effects of other therapies (e.g. chemotherapy), mitigates chronic inflammation, and stimulates an immune attack on the tumor.
The CureLab Oncology team has completed its international Phase I/IIa Clinical Trials of Elenagen™. The vaccine demonstrated a high degree of safety as well as clinical benefits in a number of patients. Based on these successful results, we initiated Phase II Clinical Trials outside of the United States, and are now preparing Phase II Clinical Trials within the US.
Location: United States, Massachusetts, Boston
Member count: 11-50
Total raised: $3M
Founded date: 2000
Funding Rounds 1
| Date | Series | Amount | Investors | Deal News |
| 02.03.2023 | - | $3M | - | finsmes.co... |
Mentions in press and media 3
| Date | Title | Description | Category | Author | Source |
| 02.03.2023 | CureLab Ra... | CureLab, a Boston, MA-based bi... | USA | - | finsmes.co... |
| 19.04.2022 | University... | CureLab Veterinary Inc. is a b... | - | - | prweb.com/... |
| - | CureLab On... | “CureLab Oncology is a biotech... | - | - | fastfounde... |